Table 1

Baseline characteristics

CharacteristicStable group, n = 2504Comparator group, n = 3569P
Mean age,* y (SD) 72.3 (10.9) 68.8 (13.1) < .001 
Age older than 70 y, % 63.0 51.5 < .001 
Male, % 52.0 51.5 .688 
INR target, %    
    2.0 3.9 3.3 .167 
    2.5 87.0 79.7 < .001 
    3.0 or more 9.1 17.0 < .001 
Primary indication for anticoagulation therapy, %    
    Atrial fibrillation 49.9 43.4 < .001 
    Venous thromboembolism 25.6 25.8 .856 
    Heart valve disorder 8.0 12.7 < .001 
    Other 16.5 18.1 .107 
Risk factors, %    
    Diabetes mellitus 1.6 3.5 < .001 
    Hypertension 18.2 20.2 .046 
    Heart failure 5.9 8.7 < .001 
    Prior venous thrombosis 2.5 3.7 .012 
    Prior hemorrhage 1.2 2.0 .021 
    Prior stroke 0.0 0.1 .273 
    Cancer 0.2 0.6 .060 
    Estrogen therapy 7.8 10.7 < .001 
Mean chronic disease score (SD) 6.5 (2.6) 6.7 (2.7) < .001 
Median duration of warfarin therapy, d§ (IQR) 1166 (554, 2051) 755 (725, 1753) .743 
CharacteristicStable group, n = 2504Comparator group, n = 3569P
Mean age,* y (SD) 72.3 (10.9) 68.8 (13.1) < .001 
Age older than 70 y, % 63.0 51.5 < .001 
Male, % 52.0 51.5 .688 
INR target, %    
    2.0 3.9 3.3 .167 
    2.5 87.0 79.7 < .001 
    3.0 or more 9.1 17.0 < .001 
Primary indication for anticoagulation therapy, %    
    Atrial fibrillation 49.9 43.4 < .001 
    Venous thromboembolism 25.6 25.8 .856 
    Heart valve disorder 8.0 12.7 < .001 
    Other 16.5 18.1 .107 
Risk factors, %    
    Diabetes mellitus 1.6 3.5 < .001 
    Hypertension 18.2 20.2 .046 
    Heart failure 5.9 8.7 < .001 
    Prior venous thrombosis 2.5 3.7 .012 
    Prior hemorrhage 1.2 2.0 .021 
    Prior stroke 0.0 0.1 .273 
    Cancer 0.2 0.6 .060 
    Estrogen therapy 7.8 10.7 < .001 
Mean chronic disease score (SD) 6.5 (2.6) 6.7 (2.7) < .001 
Median duration of warfarin therapy, d§ (IQR) 1166 (554, 2051) 755 (725, 1753) .743 

INR indicates international normalized ratio; IQR, interquartile range; and SD, standard deviation.

*

As of date of index INR measurement.

During the 180 days before the index INR.

During the 90 days before the index INR.

§

From initiation of warfarin therapy.

or Create an Account

Close Modal
Close Modal